[e-drug] How India tackles adverse drug reactions by ignoring data - A Debate (2)

e-drug
1

E-DRUG: How India tackles adverse drug reactions by ignoring data - A Debate (2)
----------------------------------------------------------------------------------------------------

With world's third largest medicine market, India is lagging behind in
ADR. A cell was started in the Drugs Controller of India ( DCI) office,
many years back. Most of the time, the cell or the group of people are not
vociferous enough to move it forward.

Even leading MNCs and Transnational Pharma companies are ignoring the ADR reporting. Medical practitioners and big corporate hospitals should develop a mind set
to monitor the ADR.

Hope the DCI and other prominent members of Indian regulators take ADR and
Pharmacovigilence as a very serious matter.

Sridharan Rangachari
Ex. National Procurement Officer, UNOPS-India
Sri <sri.chari@gmail.com>

2

E-DRUG: How India tackles adverse drug reactions by ignoring data - A Debate (3)
-------------------------------------------------------------------------------------------------

Dear E-Drug
When I shared my observation to Drugs Controller General of India office,
I got the following reply:

Dear Mr. Rangachari,

This is to inform you that The Pharmacovigilance Program of India is
capturing Adverse Drug Reaction from almost 200 medical colleges and so far
almost 1.4 lakh ADR has been captured from different part of the country.
Kindly visit the website of Pharmacovigilance Programme of India.

Regards,

Professor S. K. Gupta,
PhD, DSc (Hon), FIACS, FIPS, FISER, FRAMS*
National Advisor, Pharmacovigilance Programme of India (PvPI),
= = = = = = = = = =

India must have started ADR reporting but I personally feel that, even
though a beginning is made, it is insufficient to capture the whole country.*
I also note from the internet that The World Health Organisation's
Uppsala Monitoring Centre is now looking to make India as a hub for
Pharmacovigilance training.

The Organisation recognised India's concerted
efforts in the area of Pharmacovigilance but observed that the country
needed to play a bigger role in the global landscape of adverse drug
reaction (ADR) monitoring.

Hope a sustained efforts are made by all stake holders to derive the
benefits of ADR reporting.

Sridharan Rangachari
Ex. National Procurement Officer, UNOPS-India
Sri <sri.chari@gmail.com>